Table 2 Patient demographics and pathologic features after propensity-score matching
Characteristics | PTC with GD (n = 114) | PTC without GD (n = 570) | p value |
|---|---|---|---|
Age (years) | 46.3 ± 12.9 | 46.3 ± 12.1 | 0.960 |
Female sex | 99 (86.8%) | 486 (85.3%) | 0.662 |
Body mass index (kg/m2) | 23.8 ± 3.1 | 23.5 ± 3.1 | 0.422 |
Preoperative FNA results | 0.142 | ||
Benign | 0 (0.0%) | 9 (1.6%) | |
Atypia | 7 (6.1%) | 26 (4.6%) | |
Follicular neoplasm | 0 (0.0%) | 22 (3.9%) | |
Suspicious malignancy | 30 (26.3%) | 139 (24.4%) | |
Malignancy | 77 (67.5%) | 374 (65.6%) | |
Pathologic features | |||
Tumor size (cm) | 0.8 ± 0.5 | 0.7 ± 0.4 | 0.386 |
Extrathyroidal extension | 0.959 | ||
No | 59 (51.8%) | 290 (50.9%) | |
Microscopic | 51 (44.7%) | 257 (45.1%) | |
Gross | 4 (3.5%) | 23 (4.0%) | |
Lymphatic invasion | 2 (1.8%) | 10 (1.8%) | 1.000 |
Vascular invasion | 0 (0.0%) | 0 (0.0%) | NA |
Margin involvement | 1 (0.9%) | 5 (0.9%) | 1.000 |
LN metastasis | 0.648 | ||
N0 | 80 (70.2%) | 412 (72.3%) | |
N1a | 34 (29.8%) | 158 (27.7%) | |
N1b | 0 (0.0%) | 0 (0.0%) | |
131I remnant ablation | 43 (37.7%) | 236 (41.4%) | 0.465 |
131I dose (mCi) | 47.2 ± 32.8 | 43.9 ± 42.6 | 0.636 |
Follow-up (months) | 96.8 ± 29.5 | 94.0 ± 31.2 | 0.894 |
Recurrence | 0.557 | ||
Regional recurrence | 1 (0.9%) | 6 (1.6%) | |
Distant metastasis | 0 (0.0%) | 0 (0.0%) | |